Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

RYZNEUTA

EFBEMALENOGRASTIM ALFA-VUXW

Standard Dose
20MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview RYZNEUTA is listed in Drugs@FDA under application 761134 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient EFBEMALENOGRASTIM ALFA-VUXW Form and strength INJECTABLE;INJECTION - 20MG/ML Sponsor EVIVE BIOTECHNOLOGY Submission history Latest submission status date: 2023-11-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview RYZNEUTA is listed in Drugs@FDA under application 761134 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient EFBEMALENOGRASTIM ALFA-VUXW Form and strength INJECTABLE;INJECTION - 20MG/ML Sponsor EVIVE BIOTECHNOLOGY Submission history Latest submission status date: 2023-11-16 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.